Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold

DEVICE2 trials

Sponsors

Biotronik AG

Conditions

Acute Coronary SyndromesAngina PectorisAtherosclerosis of Coronary ArteryCoronary Artery DiseaseIschemic Heart DiseaseMyocardial Ischemia

Unknown Phase

First in Men Study: BIOMAG-I

Active, not recruitingNCT04157153

Biotronik AGCoronary Artery Disease

Start: 2020-04-27End: 2027-02-28Updated: 2022-07-22

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

RecruitingNCT07091682

Biotronik AGAcute Coronary Syndromes, Angina Pectoris, Atherosclerosis of Coronary Artery +3

Start: 2025-02-18End: 2031-06-01Target: 100Updated: 2026-07-08

Related Papers

The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months

Catheterization and Cardiovascular Interventions2025-03-16

A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study

EuroIntervention2023-08-0148 citations

Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.

2023-04-1728 citations